Pharmacotherapy for smoking cessation: Current advances and research topics

CNS Drugs

Volumn 25, Issue 5, 2011, Pages 371-382

  Raupach, Tobias ^a   Van Schayck, Constant P ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Bupropion, general; Gender differences; Nicotine abuse vaccine, general; Nicotine replacement therapy, general; Pharmacoeconomics; Pharmacogenetics; Pregnancy; Reimbursement; Smoking; Smoking withdrawal; Varenicline, general

Indexed keywords

AMFEBUTAMONE; BACLOFEN; DRUGS USED IN THE TREATMENT OF ADDICTION; GABAPENTIN; N,N DODECANE 1,12 DIYLBIS PICOLINIUM DIBROMIDE; NICOTINE VACCINE; NICOTINIC RECEPTOR; OLANZAPINE; SELEGILINE; UCI 30002; UNCLASSIFIED DRUG; VARENICLINE;

ALTERNATIVE MEDICINE; ARTICLE; DRUG RESEARCH; HUMAN; NICOTINE REPLACEMENT THERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; SMOKING CESSATION; TOBACCO DEPENDENCE;

ADMINISTRATION, TOPICAL; BUPROPION; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; NICOTINE; NICOTINIC AGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME;

EID: 79953862800     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11590620-000000000-00000     Document Type: Article

References (117)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006 Nov; 3 (11): e442
2. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005 Feb 15; 142 (4): 233-9 (Pubitemid 40216240)
3. Fiore MC, Jaen CR, Baker TB. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service, 2008 May
4. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2008; (2): CD000165
5. Nides M. Update on pharmacologic options for smoking cessation treatment. Am J Med 2008 Apr; 121 (4 Suppl. 1): S20-31 (Pubitemid 351395277)
6. Rose JE, Herskovic JE, Behm FM, et al. Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment. Nicotine Tob Res 2009 Sep; 11 (9): 1067-75
7. Etter JF, Huguelet P, Perneger TV, et al. Nicotine gum treatment before smoking cessation: a randomized trial. Arch Intern Med 2009 Jun 8; 169 (11): 1028-34
8. Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002 Sep 11; 288 (10): 1260-4 (Pubitemid 35001329)
9. West R, Zhou X. Is nicotine replacement therapy for smoking cessation effective in the "real world"? Findings from a prospective multinational cohort study. Thorax 2007 Nov; 62 (11): 998-1002 (Pubitemid 350084500)
10. Burns EK, Levinson AH. Discontinuation of nicotine replacement therapy among smoking-cessation attempters. Am J Prev Med 2008 Mar; 34 (3): 212-5 (Pubitemid 351220941)
11. Wiggers LC, Smets EM, Oort FJ, et al. Adherence to nico-tine replacement patch therapy in cardiovascular patients. Int J Behav Med 2006; 13 (1): 79-88 (Pubitemid 44139061)
12. Shiffman S, Sweeney CT, Ferguson SG, et al. Relationship between adherence to daily nicotine patch use and treatment efficacy: secondary analysis of a 10-week randomized, double-blind, placebo-controlled clinical trial simulating over-the-counter use in adult smokers. Clin Ther 2008 Oct; 30 (10): 1852-8
13. Raupach T, Shahab L, Eimer S, et al. Increasing the use of nicotine replacement therapy by a simple intervention: an exploratory trial. Subst Use Misuse 2010 Feb; 45 (3): 403-13
14. Schneider NG, Olmstead RE, Nides M, et al. Comparative testing of 5 nicotine systems: initial use and preferences. Am J Health Behav 2004 Jan-Feb; 28 (1): 72-86 (Pubitemid 38530534)
15. Vogt F, Hall S, Marteau TM. Understanding why smokers do not want to use nicotine dependence medications to stop smoking: qualitative and quantitative studies. Nicotine Tob Res 2008 Aug; 10 (8): 1405-13
16. Kaper J, Wagena EJ, Willemsen MC, et al. A randomized controlled trial to assess the effects of reimbursing the costs of smoking cessation therapy on sustained abstinence. Addiction 2006 Nov; 101 (11): 1656-61 (Pubitemid 44527198)
17. Kaper J, Wagena EJ, van Schayck CP, et al. Encouraging smokers to quit: the cost effectiveness of reimbursing the costs of smoking cessation treatment. Pharmacoeconomics 2006; 24 (5): 453-64 (Pubitemid 43765215)
18. Kaper J, Wagena EJ, Willemsen MC, et al. Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trial. Addiction 2005 Jul; 100 (7): 1012-20 (Pubitemid 40897296)
19. Liu F. Effect of Medicaid coverage of tobacco-dependence treatments on smoking cessation. Int J Environ Res Public Health 2009 Dec; 6 (12): 3143-55
20. Petersen R, Garrett JM, Melvin CL, et al. Medicaid re-imbursement for prenatal smoking intervention influences quitting and cessation. Tob Control 2006 Feb; 15 (1): 30-4 (Pubitemid 43190319)
21. Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010; 340: b5569
22. Schuller HM. Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2002 Jun; 2 (6): 455-63 (Pubitemid 37328942)
23. Yamanaka H, Nakajima M, Fukami T, et al. CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab Dispos 2005 Dec; 33 (12): 1811-8 (Pubitemid 41697266)
24. Heusch WL, Maneckjee R. Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. Carcinogenesis 1998 Apr; 19 (4): 551-6 (Pubitemid 28376796)
25. Davis R, Rizwani W, Banerjee S, et al. Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One 2009; 4 (10): e7524
26. Murray RP, Connett JE, Zapawa LM. Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. Nicotine Tob Res 2009 Sep; 11 (9): 1076-82
27. Arias HR. Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? Int J Biochem Cell Biol 2009 Nov; 41 (11): 2098-108
28. Paterson NE. Behavioural and pharmacological mechan-isms of bupropion's anti-smoking effects: recent pre-clinical and clinical insights. Eur J Pharmacol 2009 Jan 28; 603 (1-3): 1-11
29. Van Schayck CP, Kaper J, Wagena EJ, et al. The cost-effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients. Addiction 2009 Dec; 104 (12): 2110-7
30. Levine MD, Perkins KA, Kalarchian MA, et al. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. Arch Intern Med 2010 Mar 22; 170 (6): 543-50
31. Wilcox CS, Oskooilar N, Erickson JS, et al. An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. Addict Behav 2010 Mar; 35 (3): 229-34
32. Parsons AC, Shraim M, Inglis J, et al. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2009; (1): CD006219
33. Fucito LM, Toll BA, Salovey P, et al. Beliefs and attitudes about bupropion: implications for medication adherence and smoking cessation treatment. Psychol Addict Behav Jun; 23 (2): 373-9
34. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2008; (3): CD006103
35. West R, Baker CL, Cappelleri JC, et al. Effect of vareni-cline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl) 2008 Apr; 197 (3): 371-7
36. Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation Jan 19; 121 (2): 221-9
37. Bolin K, Wilson K, Benhaddi H, et al. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation: results from four European countries. Eur J Public Health 2009 Dec; 19 (6): 650-4
38. Keiding H. Cost-effectiveness of varenicline for smoking cessation. Expert Rev Pharmacoecon Outcomes Res 2009 Jun; 9 (3): 215-21
39. Blak BT, Wilson K, Metcalfe M, et al. Evaluation of var-enicline as an aid to smoking cessation in UK general practice: a THIN database study. Curr Med Res Opin 2010 Apr; 26 (4): 861-70
40. Hajek P, Tonnesen P, Arteaga C, et al. Varenicline in pre-vention of relapse to smoking: effect of quit pattern on response to extended treatment. Addiction 2009 Sep; 104 (9): 1597-602
41. Gunnell D, Irvine D, Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805
42. Stapleton J. Do the 10 UK suicides among those taking the smoking cessation drug varenicline suggest a causal link? Addiction 2009 May; 104 (5): 864-5
43. Tonstad S, Davies S, Flammer M, et al. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf 2010 Apr 1; 33 (4): 289-301
44. Henningfield JE, Shiffman S, Ferguson SG, et al. Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy. Pharmacol Ther 2009 Jul; 123 (1): 1-16
45. Lerman C, LeSage MG, Perkins KA, et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 2007 Sep; 6 (9): 746-62 (Pubitemid 47338182)
46. Sood A, Ebbert JO, Wyatt KD, et al. Gabapentin for smoking cessation. Nicotine Tob Res 2010 Mar; 12 (3): 300-4
47. Weinberger AH, Reutenauer EL, Jatlow PI, et al. A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. Drug Alcohol Depend 2010 Mar 1; 107 (2-3): 188-95
48. Franklin TR, Harper D, Kampman K, et al. The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend 2009 Jul 1; 103 (1-2): 30-6
49. Rohsenow DJ, Tidey JW, Miranda R, et al. Olanzapine reduces urge to smoke and nicotine withdrawal symptoms in community smokers. Exp Clin Psychopharmacol 2008 Jun; 16 (3): 215-22 (Pubitemid 351822565)
50. Balfour DJ. Neural mechanisms underlying nicotine dependence. Addiction 1994 Nov; 89 (11): 1419-23 (Pubitemid 24343900)
51. Dwoskin LP, Smith AM, Wooters TE, et al. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochem Pharmacol 2009 Oct 1; 78 (7): 732-43
52. Grady SR, Murphy KL, Cao J, et al. Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions. J Pharmacol Exp Ther 2002; 301 (2): 651-60 (Pubitemid 34429981)
53. Zatonski W, Cedzynska M, Tutka P, et al. An uncontrolled trial of cytisine (Tabex) for smoking cessation. Tob Control 2006 Dec; 15 (6): 481-4 (Pubitemid 44935576)
54. Zwart R, Carbone AL, Moroni M, et al. Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors. Mol Pharmacol 2008 Jun; 73 (6): 1838-43 (Pubitemid 351724371)
55. Rose JE, Behm FM, Westman EC, et al. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 1994 Jul; 56 (1): 86-99 (Pubitemid 24251569)
56. Yoshimura RF, Hogenkamp DJ, Li WY, et al. Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats. J Pharmacol Exp Ther 2007 Dec; 323 (3): 907-15 (Pubitemid 350146068)
57. 0-dodecane-1, 12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats. Psychopharmacology (Berl) 2006 Mar; 184 (3-4): 426-34 (Pubitemid 43255859)
58. Buchhalter AR, Fant RV, Henningfield JE. Novel phar-macological approaches for treating tobacco dependence and withdrawal: current status. Drugs 2008; 68 (8): 1067-88 (Pubitemid 351693676)
59. Liechti ME, Markou A. Role of the glutamatergic system in nicotine dependence: implications for the discovery and development of new pharmacological smoking cessation therapies. CNS Drugs 2008; 22 (9): 705-24
60. Le Foll B, Forget B, Aubin HJ, et al. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol 2008 Jun; 13 (2): 239-52 (Pubitemid 351692986)
61. Rigotti NA, Gonzales D, Dale LC, et al. A randomized controlled trial of adding the nicotine patch to rimona-bant for smoking cessation: efficacy, safety and weight gain. Addiction 2009 Feb; 104 (2): 266-76
62. Stapleton JA. Trial comes too late as psychiatric side effects end hope for rimonabant. Addiction 2009 Feb; 104 (2): 277-8
63. Cerny EH, Cerny T. Vaccines against nicotine. Hum Vaccin 2009 Apr; 5 (4): 200-5
64. de Villiers SH, Lindblom N, Kalayanov G, et al. Nicotine hapten structure, antibody selectivity and effect relation-ships: results from a nicotine vaccine screening procedure. Vaccine 2010 Mar 2; 28 (10): 2161-8
65. Leader AE, Lerman C, Cappella JN. Nicotine vaccines: will smokers take a shot at quitting? Nicotine Tob Res 2010 Apr; 12 (4): 390-7
66. Wagena EJ, de Vos A, Horwith G, et al. The immuno-genicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial. Nicotine Tob Res 2008 Jan; 10 (1): 213-8
67. Cornuz J, Zwahlen S, Jungi WF, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008; 3 (6): e2547
68. Ebbert JO, Hays JT, Hurt RD. Combination pharmacotherapy for stopping smoking: what advantages does it offer? Drugs 2010 Apr 16; 70 (6): 643-50
69. Blondal T, Gudmundsson LJ, Olafsdottir I, et al. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. BMJ 1999 Jan 30; 318 (7179): 285-8
70. Bohadana A, Nilsson F, Rasmussen T, et al. Nicotine in-haler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2000 Nov 13; 160 (20): 3128-34
71. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; (1): CD000146
72. Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009 Nov; 66(11): 1253-62
73. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999 Mar 4; 340 (9): 685-91 (Pubitemid 29110752)
74. Smith SS, McCarthy DE, Japuntich SJ, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med 2009 Dec 14; 169 (22): 2148-55
75. Croghan IT, Hurt RD, Dakhil SR, et al. Randomized com-parison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc 2007 Feb; 82 (2): 186-95 (Pubitemid 46198478)
76. Steinberg MB, Greenhaus S, Schmelzer AC, et al. Triplecombination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med 2009 Apr 7; 150 (7): 447-54
77. Prochazka AV, Kick S, Steinbrunn C, et al. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004 Nov 8; 164 (20): 2229-33 (Pubitemid 39452983)
78. Aveyard P, Johnson C, Fillingham S, et al. Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial. BMJ 2008 May 31; 336 (7655): 1223-7 (Pubitemid 351809316)
79. Ebbert JO, Burke MV, Hays JT, et al. Combination treat-ment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009 May; 11 (5): 572-6
80. Ebbert JO, Croghan IT, Sood A, et al. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res 2009 Mar; 11 (3): 234-9
81. Kortmann GL, Dobler CJ, Bizarro L, et al. Pharmaco-genetics of smoking cessation therapy. Am J Med Genet B Neuropsychiatr Genet 2010 Jan 5; 153B (1): 17-28
82. Malaiyandi V, Lerman C, Benowitz NL, et al. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 2006 Apr; 11 (4): 400-9
83. Schnoll RA, Patterson F, Wileyto EP, et al. Nicotine me-tabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol Biochem Behav 2009 Mar; 92 (1): 6-11
84. Lerman C, Jepson C, Wileyto EP, et al. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clin Pharmacol Ther 2010 May; 87 (5): 553-7
85. Patterson F, Schnoll RA, Wileyto EP, et al. Toward per-sonalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 2008 Sep; 84 (3): 320-5
86. Ray R, Tyndale RF, Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet 2009; 23 (3): 252-61
87. David SP, Munafo MR, Murphy MF, et al. Genetic var-iation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J 2008 Apr; 8 (2): 122-8 (Pubitemid 351411548)
88. Perkins KA, Lerman C, Fonte CA, et al. Cross-validation of a new procedure for early screening of smoking cessation medications in humans. Clin Pharmacol Ther 2010 Jul; 88 (1): 109-14
89. Perkins KA, Lerman C, Stitzer M, et al. Development of procedures for early screening of smoking cessation medications in humans. Clin Pharmacol Ther 2008 Aug; 84 (2): 216-21
90. Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ 2009; 338: b1024
91. Solberg LI, Parker ED, Foldes SS, et al. Disparities in to-bacco cessation medication orders and fills among special populations. Nicotine Tob Res 2010 Feb; 12 (2): 144-51
92. Robles GI, Singh-Franco D, Ghin HL. A review of the efficacy of smoking-cessation pharmacotherapies in non-white populations. Clin Ther 2008 May; 30 (5): 800-12 (Pubitemid 351802284)
93. Baha MY, Le Faou AL. Smoking cessation interventions offered to French adult light smokers: a heterogeneous population with specific needs. Eur Addict Res 2010 May 7; 16 (3): 162-9
94. Oncken CA, Kranzler HR. What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy? Nicotine Tob Res 2009 Nov; 11 (11): 1265-73
95. Ussher M, Aveyard P, Coleman T, et al. Physical activity as an aid to smoking cessation during pregnancy: two feasibility studies. BMC Public Health 2008; 8: 328
96. Swan GE, Jack LM, Curry S, et al. Bupropion SR and counseling for smoking cessation in actual practice: pre-dictors of outcome. Nicotine Tob Res 2003 Dec; 5 (6): 911-21 (Pubitemid 38029087)
97. Cepeda-Benito A, Reynoso JT, Erath S. Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. J Consult Clin Psychol 2004 Aug; 72 (4): 712-22 (Pubitemid 38988848)
98. Burgess DJ, Fu SS, Noorbaloochi S, et al. Employment, gender, and smoking cessation outcomes in low-income smokers using nicotine replacement therapy. Nicotine Tob Res 2009 Dec; 11 (12): 1439-47
99. Kotz D, West R. Explaining the social gradient in smok-ing cessation: it's not in the trying, but in the succeeding. Tob Control 2009 Feb; 18 (1): 43-6
100. Jha P, Peto R, Zatonski W, et al. Social inequalities in male mortality, and in male mortality from smoking: indirect estimation from national death rates in England and Wales, Poland, and North America. Lancet 2006 Jul 29; 368 (9533): 367-70 (Pubitemid 44108096)
101. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006 Jul 5; 296 (1): 47-55
102. Etter JF, Stapleton J. Citations to trials of nicotine replacement therapy were biased toward positive results and high-impact-factor journals. J Clin Epidemiol 2009 Aug; 62 (8): 831-7
103. Walsh RA. Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness. Drug Alcohol Rev 2008 Sep; 27 (5): 529-47
104. McEwen A, West R. Do implementation issues influence the effectiveness of medications? The case of nicotine replacement therapy and bupropion in UK Stop Smoking Services. BMC Public Health 2009; 9: 28
105. Grassi MC, Enea D, Ferketich AK, et al. A smoking ban in public places increases the efficacy of bupropion and counseling on cessation outcomes at 1 year. Nicotine Tob Res 2009 Sep; 11 (9): 1114-21
106. Krist AH, Woolf SH, Johnson RE, et al. Patient costs as a barrier to intensive health behavior counseling. Am J Prev Med 2010 Mar; 38 (3): 344-8
107. Chapman S, MacKenzie R. The global research neglect of unassisted smoking cessation: causes and consequences. PLoS Med 2010; 7 (2): e1000216
108. Fiore MC, Novotny TE, Pierce JP, et al. Methods used to quit smoking in the United States: do cessation programs help? JAMA 1990 May 23-30; 263 (20): 2760-5 (Pubitemid 20181569)
109. West R, Sohal T. 'Catastrophic' pathways to smoking cessation: findings from national survey. BMJ 2006 Feb 25; 332 (7539): 458-60 (Pubitemid 43342044)
110. Cornuz J, Gilbert A, Pinget C, et al. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tob Control 2006 Jun; 15 (3): 152-9 (Pubitemid 43864869)
111. Annemans L, Nackaerts K, Bartsch P, et al. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin Drug Investig 2009; 29 (10): 655-65
112. Hoogendoorn M, Welsing P, Rutten-van Molken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008 Jan; 24 (1): 51-61 (Pubitemid 351160238)
113. Linden K, Jormanainen V, Linna M, et al. Cost effective-ness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Curr Med Res Opin 2010 Mar; 26 (3): 549-60
114. Vemer P, Rutten-van Molken MP. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health 2010 Mar-Apr; 13 (2): 230-41
115. Orleans CT. Increasing the demand for and use of effective smoking-cessation treatments reaping the full health bene-fits of tobacco-control science and policy gains: in our lifetime. Am J Prev Med 2007 Dec; 33 (6 Suppl.): S340-8 (Pubitemid 350087620)
116. Chapman KR. Chronic obstructive pulmonary disease: are women more susceptible than men? Clin Chest Med 2004 Jun; 25 (2): 331-41 (Pubitemid 38507652)
117. Henschke CI, Miettinen OS. Women's susceptibility to tobacco carcinogens. Lung Cancer 2004 Jan; 43 (1): 1-5 (Pubitemid 38096286)